TRT Jatenzo denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for trt jatenzo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Uses Step Therapy for Jatenzo — and How to Appeal a Step-Therapy Denial

Step therapy (also called "fail first") requires you to try one or more lower-cost or preferred formulary drugs before the plan will cover a non-preferred or more expensive alternative. For Jatenzo (testosterone undecanoate oral), Aetna typically requires that a patient have tried and failed — or have a documented clinical reason to avoid — lower-tier testosterone formulations (such as generic topical gels or injectable testosterone) before approving the brand-name oral capsule. A step-therapy denial does not mean Jatenzo is inappropriate; it means the plan wants documented evidence about prior therapy.

## Why Step-Therapy Denials Are Frequently Overturned

Step-therapy exceptions are well-established in both federal and state law. Most states have enacted step-therapy exception laws requiring insurers to approve a non-preferred drug when the required first-step drug is contraindicated, would cause an adverse reaction, has already been tried and failed, or is otherwise clinically inappropriate for the individual patient. Even in states without such laws, ERISA and ACA appeal rights allow a medical-necessity argument that the specific clinical circumstances support skipping to Jatenzo directly.

## Federal and State Appeal Framework

Under ACA Section 2719 and ERISA Section 503, you have the right to a full internal appeal and independent external review. Approximately four months after a final internal denial, you can request external review from an independent review organization. Expedited review is available when delay poses a serious health risk. Separately, check whether your state has enacted a step-therapy exception statute — many require a decision within 72 hours on expedited requests.

## What to Gather Before You Appeal

• Aetna's step-therapy policy for testosterone products. Obtain the full published criteria so you know exactly which step(s) are required and what constitutes documented failure or exception.
• Prior treatment history with dates and outcomes. For each required prior drug, the prescriber should document: the drug tried, the dates, the outcome (failed to achieve therapeutic goal, caused adverse effect, was contraindicated, etc.). Specific chart notes and pharmacy records carry more weight than general statements.
• Prescriber medical-necessity letter. The letter should address each step in Aetna's protocol by name and explain — with chart-based facts — why those steps either have been completed or are clinically inappropriate for this patient. The letter should also explain what clinical characteristics make Jatenzo (oral route) specifically appropriate.
• Diagnosis and severity documentation. Records confirming the hypogonadism diagnosis, its severity, and any complicating factors that affect route-of-administration choices (e.g., skin conditions affecting topical absorption, patient-specific injection barriers, etc.).

## Criteria-Mapping Structure

| Aetna step-therapy requirement | Chart evidence | Document | |---|---|---| | Required step 1 drug tried | Dates, pharmacy records | Chart notes + Rx history | | Outcome of step 1 (failed / adverse / contraindicated) | Clinical documentation | Prescriber notes | | Clinical reason Jatenzo is the appropriate next step | Prescriber letter | Letter, date |

## Timeline

Submit the internal appeal promptly. Include all documentation in the first submission — appeals that require back-and-forth with the plan take longer. If the prescriber requests a peer-to-peer review simultaneously, that often resolves step-therapy denials without requiring full external review.